Retraction Note to: The EQ-5D-5L Valuation Study in Egypt

Sahar A. Al Shabasy¹ · Maggie M. Abbassi¹ · Aureliano Paolo Finch² · Darrin Baines³ · Samar F. Farid¹

Published online: 15 June 2021
© The Author(s) 2021

Retraction to:

PharmacoEconomics (2021) 39:549–561
<https://doi.org/10.1007/s40273-021-01002-z>

The authors have retracted this article because there is an inconsistency in the preferred model (model 4). This will lead to the worst health state (55555) receiving a higher value than 55455 and will obviously affect the values of other health states as well. All authors agree with this retraction. The authors have been invited to submit a new manuscript using a different model for peer review.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <https://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40273-021-01002-z>.

✉ Samar F. Farid
samar.farid@pharma.cu.edu.eg

¹ Department of Clinical Pharmacy, Faculty of Pharmacy,
Cairo University, Kasr El-Aini St., Cairo 11562, Egypt

² EuroQol Group Office, Rotterdam, The Netherlands

³ Business School, Dorset House Talbot Campus,
Bournemouth University, Fern Barrow, Poole, UK